Pfizer, Inc. — PFE
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $24.68 | $140.35B | 13.1 | 8.4 | 6.8% | 2.4% | $1.72 701.0% | 1.6 |
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $41.7B | $9.2B | $1.73 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $81.3B | $22.0B | $3.92 | 95.2% | 140.0% | 126.6% |
| 2 | 2022-12-31 | $100.3B | $31.4B | $5.59 | 23.4% | 42.7% | 42.6% |
| 3 | 2023-12-31 | $58.5B | $2.1B | $0.38 | -41.7% | -93.2% | -93.2% |
| 4 | 2024-12-31 | $63.6B | $8.0B | $0.38 | 8.8% | 279.0% | 0.0% |
| 5 | TTM 2025-03-31 | $62.5B | $7.9B | $1.38 | -1.8% | -1.8% | 263.2% |
| 6 | Average | 16.8% | 73.3% | 67.8% |
EPS
Forecasts
Y/Y % Change
PFE Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 95.2% | 23.4% | -41.7% | 8.8% | 0.2% | -1.4% | 14.1% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 5 | 5 | |
| EPS Growth (%) | 140.0% | 42.7% | -93.2% | 279.0% | 121.6% | -1.3% | 81.5% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2021 | $81.3B | $24.1B | $10.4B | $12.7B | $5.2B |
| 2022 | $101.2B | $27.8B | $11.4B | $13.7B | $5.1B |
| 2023 | $59.6B | $17.1B | $10.7B | $14.8B | $6.3B |
| 2024 | $63.6B | $9.1B | $10.8B | $14.7B | $7.0B |
| TTM | $63.8B | $9.3B | $10.3B | $14.0B | $6.8B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | 24.46 | 15.27 | 10.31 | 7.67 | -2.45 |
| 2023 | -41.14 | -38.52 | -6.55 | 8.00 | 24.21 |
| 2024 | 6.84 | -46.74 | 1.34 | -0.28 | 11.49 |
| TTM | 0.32 | 2.18 | -4.66 | -5.20 | -3.19 |
No unmapped expenses.
Segment Performance
SEGMENTS v2025-09-09 · 2025-09-05 15:05 UTC — Values are shown in a single scale for this table: $B. TTM values are bold. “% of Total (TTM)” shows revenue mix.
| Segment | 2022 Rev ($B) | 2022 OI ($B) | 2023 Rev ($B) | 2023 OI ($B) | 2024 Rev ($B) | 2024 OI ($B) | TTM Rev ($B) | TTM OI ($B) | % of Total (TTM) |
|---|---|---|---|---|---|---|---|---|---|
| Product | 92.2B | 0.00B | 51.1B | 0.00B | 54.0B | 0.00B | 89.2B | 0.00B | 93.2% |
| Royalty | 2.30B | 0.00B | 2.72B | 0.00B | 3.77B | 0.00B | 6.09B | 0.00B | 6.4% |
| Paxlovid N D A Labeled U S Strategic National Stockpile | – | – | – | – | 1.33B | 0.00B | 0.44B | 0.00B | 0.5% |
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $208,028M |
| 1 | Cash | $1,430M |
| 2 | Total Liabilities | $117,391M |
| 3 | Total Debt | $61,291M |
| 4 | Total Equity | $90,338M |
| 5 | Debt to Equity Ratio | 0.68 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $23.97 | 4.4% | Nicks Growth: 2% Nick's Expected Margin: 10% FINVIZ Growth: -0% |
Nicks: 8 Finviz: 6 |
Nick's: 0.786 | 2.2 | 17.4 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $1.38 EPS | TTM | $10.85 | -54.7% | $8.58 | -64.2% |
| $3.06 EPS | 2025 | $24.06 | 0.4% | $19.02 | -20.7% |
| $3.09 EPS | 2026 | $24.30 | 1.4% | $19.20 | -19.9% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 8.99% | 2.65% | 10.01% | 2.67% | 1.67% | 0.28% | 6.93% | 2.42% | 6.9% | 17.2% |
| 3 Years | 8.99% | 2.65% | 10.01% | 2.67% | 1.67% | 0.28% | 6.93% | 2.42% | 6.9% | 17.2% |
| 5 Years | 8.99% | 2.65% | 10.01% | 2.67% | 1.67% | 0.28% | 6.93% | 2.42% | 6.9% | 17.2% |
| 10 Years | 8.99% | 2.65% | 10.01% | 2.67% | 1.67% | 0.28% | 6.93% | 2.42% | 6.9% | 17.2% |